Atopic Keratoconjunctivitis Market Summary

• According to DelveInsight, Atopic Keratoconjunctivitis Market is expected to grow at a decent CAGR by 2032.
• Atopic Keratoconjunctivitis Companies are Aldeyra Therapeutics, Vanda Pharmaceuticals, Noveome Biotherapeutics, Allakos, Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, JW Pharmaceutical, Nanomerics, OKYO Pharma, RAPT Therapeutics, Allakos, Sylentis, Postbiotica, Stuart Therapeutics, Oyster Point Pharma, Bausch Health Companies Inc., Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL,Roxall Medicina España S.A, Biomay AG, and others.

Factors Affecting Atopic Keratoconjunctivitis Market Growth

Rising Prevalence of Allergic and Atopic Conditions

The increasing incidence of allergic diseases such as atopic dermatitis, asthma, and allergic rhinitis contributes to a higher prevalence of Atopic Keratoconjunctivitis. As more individuals develop or are diagnosed with atopic conditions, the pool of patients susceptible to AKC expands, driving demand for clinical care and therapeutic products.

Growing Awareness and Early Diagnosis

Enhanced awareness among patients and healthcare professionals about ocular allergies and atopic eye disease promotes earlier diagnosis and better disease management. Increased screening and education help reduce missed or delayed diagnoses, leading to higher treatment utilization and market activity.

Advancements in Therapeutic Options

Recent innovations in treatment such as topical immunomodulators (e.g., cyclosporine, lifitegrast), novel biologics, and improved anti-inflammatory formulations offer better efficacy and safety compared with traditional therapies (e.g., corticosteroids). Advancements expand treatment choices and support broader adoption.

Increasing R&D Investment

Pharmaceutical and biotech investment into ocular allergy and immunology research fuels development of next-generation treatments. Clinical trials exploring new molecules, mechanisms, and delivery systems can strengthen the pipeline and future market growth prospects.

Emphasis on Patient Quality of Life

Atopic Keratoconjunctivitis significantly impacts daily functioning and comfort. Rising patient demand for effective, long-term symptom control and improved quality of life encourages uptake of advanced therapeutic options, especially for chronic or severe disease.

Availability of Over-the-Counter (OTC) Products

An expanding range of OTC antihistamines, artificial tears, and allergen barrier eye drops allows patients to self-manage mild symptoms. While this increases overall product usage, it can reduce clinic visits and shift demand away from prescription treatments.

Healthcare Infrastructure and Access

Regions with robust ophthalmology care networks and specialist services are better positioned to diagnose and manage AKC. Enhanced access to eye care providers, diagnostic tools, and prescription treatments supports market growth, while limited infrastructure in developing regions impedes it.

Reimbursement and Pricing Dynamics

Healthcare reimbursement policies and treatment costs influence patient access. Favorable reimbursement for prescription immunomodulators and biologics encourages utilization, whereas high drug prices and limited coverage can restrict market expansion especially in cost-sensitive regions.

Seasonal and Environmental Triggers

Environmental factors including pollen, pollution, and climate changes contribute to fluctuating disease incidence and symptom severity. Seasonal peaks in allergic responses can lead to periodic increases in product demand and clinical visits.

Competitive Landscape

The presence of multiple therapeutic classes (antihistamines, mast cell stabilizers, corticosteroids, immunomodulators, biologics) increases treatment options but also intensifies competitive pressure. Innovation differentiation, strong clinical data, and marketing strategies play crucial roles in capturing market share.

DelveInsight's "Atopic Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Atopic Keratoconjunctivitis, historical and forecasted epidemiology as well as the Atopic Keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Atopic Keratoconjunctivitis market report provides current treatment practices, emerging drugs, Atopic Keratoconjunctivitis market share of the individual therapies, current and forecasted Atopic Keratoconjunctivitis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Atopic Keratoconjunctivitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Atopic Keratoconjunctivitis market.

Atopic Keratoconjunctivitis Disease Understanding

The DelveInsight’s Atopic Keratoconjunctivitis market report gives a thorough understanding of the Atopic Keratoconjunctivitis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Atopic keratoconjunctivitis (AKC) was first described in 1952 by Hogan, who described five cases of atopic eczema associated with bilateral keratoconjunctivitis. Originally reported to flare with worsening dermatitis, atopic keratoconjunctivitis in some patients evolves independent of dermatitis.

Atopic keratoconjunctivitis is the result of a condition called "atopy". Atopy is a genetic condition where your immune system produces higher than normal antibodies in response to a given allergen. The pathophysiology is incompletely understood, but likely represents a combination of type I (IgE mediated) and type IV (delayed) hypersensitivity reactions. This involves the release of cytokines by mast cells, eosinophils, T cells and conjunctival epithelial cells. This release of allergic mediators leads to activation of T helper cells and chronic mast cell degranulation. Atopic keratoconjunctivitis is a multifactorial disease with genetic and environmental risk factors. The strongest associations are genetic predisposition for poor skin barrier function and dysregulation of the immune system, asthma, allergic rhinitis and environmental allergens. The presence of food allergies and sensitivities in infancy and childhood is associated with a more severe form of atopic dermatitis.

With Atopic keratoconjunctivitis, the conjunctiva lining the eyelids is usually red and swollen. The lower eyelid generally is affected more than the upper eyelid. This is a differentiating symptom from vernal keratoconjunctivitis where the upper eyelid is most often affected.

Atopic Keratoconjunctivitis Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Atopic Keratoconjunctivitis. Atopic Keratoconjunctivitis usually is diagnosed by clinical exam and a medical and family history, although a conjunctival biopsy may be helpful in distinguishing Atopic Keratoconjunctivitis from other conditions.

Atopic Keratoconjunctivitis Treatment

All treatment for atopic keratoconjunctivitis should be managed in conjunction with an ophthalmologist, and immediate referral is indicated when there is moderate to severe irritation, increased redness, discharge, or any visual symptoms. Atopic keratoconjunctivitis treatment options include a combination of mast cell inhibitors, antihistamines, corticosteroids, and calcineurin inhibitors.

Atopic Keratoconjunctivitis Epidemiology 

The Atopic Keratoconjunctivitis epidemiology section provides insights about the historical and current Atopic Keratoconjunctivitis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Atopic Keratoconjunctivitis market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings from Atopic Keratoconjunctivitis Epidemiological Analysis and Forecast

The disease epidemiology covered in the report provides historical as well as forecasted Atopic Keratoconjunctivitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

• As per Ghiglioni (2021), a 2008 European study reported a prevalence of 3.2 cases/10,000 people, with the highest values in Italy (0.4%–4.8%), representing up to 15% of pediatric ophthalmological outpatient visits in 46% of cases, VKC is associated with non-ocular allergic manifestations: rhinitis (30.1%), eczema (16.3%), asthma (14.6%), and urticaria (4.9%). The VKC and atopy association varies between 15% and 60%.
• As per the study conducted by Miazaki et al. (2020), in Japan, the ratio of VKC in ocular allergic patients was 3.8% and that for AKC was 4.4% in 2002–2003 (N = 1079). Moreover, an internet-based survey conducted for ophthalmologists and their families in 2017 indicated that in general population the prevalence of AKC was approximately 5.3%.

Country Wise- Atopic Keratoconjunctivitis Epidemiology

The epidemiology segment also provides the Atopic Keratoconjunctivitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Atopic Keratoconjunctivitis Drug Analysis

The drug chapter segment of the Atopic Keratoconjunctivitis report encloses the detailed analysis of Atopic Keratoconjunctivitis marketed drugs and late-stage (Phase-III and Phase-II) Atopic Keratoconjunctivitis pipeline drugs. It also helps to understand the Atopic Keratoconjunctivitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Atopic Keratoconjunctivitis Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Atopic Keratoconjunctivitis treatment.

Atopic Keratoconjunctivitis Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Atopic Keratoconjunctivitis treatment.

Dupixent (Dupilumab): Andover Eye Associates/Regeneron Pharmaceuticals

Dupixent (Dupilumab) is being developed by Andover Eye Associates in collaboration Regeneron Pharmaceuticals. The drug is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. It is not an immunosuppressant and does not require lab monitoring.

IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma, and chronic rhinosinusitis (CRSwNP). The company initiated the multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability Phase II study evaluatingthe efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC) in February 2020, while there are no recent updates by the company for the trial and the trial is still on recruiting stage.

OC-103: Oyster Point Pharma

Oyster Point Pharma’s drug OC-103 is in preclinical Phase. OC-103 (AAV-DAO) is an AAV containing the gene that encodes human diamine oxidase (DAO). DAO is a naturally occurring human enzyme responsible for breaking down excess histamine, a compound that has been shown to induce various physiological and immunological changes through histamine receptor stimulation on the ocular surface2,3. By administering OC-103 (AAV-DAO) into the lacrimal gland, our goal is to harness the body’s protein-producing machinery to produce DAO, which would then secrete this naturally present enzyme into the tear film and onto the ocular surface. In January 2023, Viatris officially acquired Oyster Point Pharma.

Atopic Keratoconjunctivitis Market Outlook

The Atopic Keratoconjunctivitis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Atopic Keratoconjunctivitis market trends by analyzing the impact of current Atopic Keratoconjunctivitis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Atopic Keratoconjunctivitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Atopic Keratoconjunctivitis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Management of atopic keratoconjunctivitis is aimed at decreasing the inflammatory response and controlling symptoms. The majority of cases are co-managed with an allergist or dermatologist to provide guidance and follow up of systemic therapy. In early disease, conservative management with combination topical mast cell stabilizers and anti-histamine drops, lubricants, cold compresses, and oral anti-histamines may keep the ocular disease under control. However, in more advanced cases, additional pharmacologic therapy is necessary. Pharmacologic therapy for these cases includes topical corticosteroid drops, cyclosporine drops, or tacrolimus ointment to the eyelid skin.

Non pharmacologic therapy is based on behavioral rules (Clinical manifestations should be controlled in order to prevent their evolution toward more severe ones.) and the use of artificial tears. Pharmacological therapy includes “Over the counter” eye drops. The most commonly used drugs are symptomatic and include antihistamines (zelastine 0.05%), mast cell stabilizers (olopatadine 0.1% or lodoxamide 0.1%), Topical NSAIDs (Indomethacin, Ketorolac, Diclofenac) and topical steroids. While almost all patients will require more intensive treatment, these are vital to efficacious treatment.

According to DelveInsight, the Atopic Keratoconjunctivitis market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings from Atopic Keratoconjunctivitis Market Report

This section includes a glimpse of the Atopic Keratoconjunctivitis market in 7MM.

Atopic Keratoconjunctivitis Regional Analysis

The United States Atopic Keratoconjunctivitis Market Outlook

This section provides the total Atopic Keratoconjunctivitis market size and market size by therapies in the United States.

EU-5 Countries Atopic Keratoconjunctivitis Market Outlook

The total Atopic Keratoconjunctivitis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Atopic Keratoconjunctivitis Market Outlook

The total Atopic Keratoconjunctivitis market size and market size by therapies in Japan is also mentioned.

Atopic Keratoconjunctivitis Drugs Uptake

This section focuses on the rate of uptake of the potential Atopic Keratoconjunctivitis drugs recently launched in the Atopic Keratoconjunctivitis market or expected to get launched in the market during the study period 2019-2032. The analysis covers Atopic Keratoconjunctivitis market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Atopic Keratoconjunctivitis Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Atopic Keratoconjunctivitis market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Atopic Keratoconjunctivitis Clinical Trial Activities

The Atopic Keratoconjunctivitis report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Atopic Keratoconjunctivitis key players involved in developing targeted therapeutics.

Atopic Keratoconjunctivitis Pipeline Development Activities

The Atopic Keratoconjunctivitis report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Atopic Keratoconjunctivitis emerging therapies.

Reimbursement Scenario in Atopic Keratoconjunctivitis

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Latest KOL- Views on Atopic Keratoconjunctivitis

To keep up with current Atopic Keratoconjunctivitis market trends, we take KOLs and SMEs ' opinion working in the Atopic Keratoconjunctivitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Atopic Keratoconjunctivitis market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

What KOLs are saying on Atopic Keratoconjunctivitis Patient Trends?

“Even when dermatologic symptoms are well-controlled, patients with AD require ophthalmic evaluation due to risks of conditions like AKC, cataracts, and retinal detachment, which can lead to vision impairment if untreated.”

“Allergic conjunctivitis encompasses various subtypes, including AKC, VKC, and GPC, each with distinct clinical features and natural histories. Healthcare practitioners must recognize and differentiate these subtypes through comprehensive patient evaluation and detailed history-taking.”

Atopic Keratoconjunctivitis Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Atopic Keratoconjunctivitis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Atopic Keratoconjunctivitis Market Report

• The Atopic Keratoconjunctivitis market report covers the descriptive overview of Atopic Keratoconjunctivitis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Atopic Keratoconjunctivitis epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Atopic Keratoconjunctivitis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Atopic Keratoconjunctivitis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The Atopic Keratoconjunctivitis market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Atopic Keratoconjunctivitis market

Atopic Keratoconjunctivitis Market Report Highlights

• In the coming years, the Atopic Keratoconjunctivitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Keratoconjunctivitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Atopic Keratoconjunctivitis. The launch of emerging therapies will significantly impact the Atopic Keratoconjunctivitis market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Atopic Keratoconjunctivitis
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Atopic Keratoconjunctivitis Market Report Insights

• Atopic Keratoconjunctivitis Patient Population
• Therapeutic Approaches
• Atopic Keratoconjunctivitis Pipeline Analysis
• Atopic Keratoconjunctivitis Market Size and Trends
• Atopic Keratoconjunctivitis Market Opportunities
• Impact of upcoming Atopic Keratoconjunctivitis Therapies

Atopic Keratoconjunctivitis Market Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Atopic Keratoconjunctivitis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Atopic Keratoconjunctivitis Market
• Atopic Keratoconjunctivitis Drugs Uptake

Atopic Keratoconjunctivitis Market Report Assessment

• Current Treatment Practices
• Atopic Keratoconjunctivitis Unmet Needs
• Atopic Keratoconjunctivitis Pipeline Product Profiles
• Atopic Keratoconjunctivitis Market Attractiveness
• Atopic Keratoconjunctivitis Market Drivers
• Atopic Keratoconjunctivitis Market Barriers

Key Questions Answered from Atopic Keratoconjunctivitis Market Report

Atopic Keratoconjunctivitis Market Insights

• What was the Atopic Keratoconjunctivitis drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Atopic Keratoconjunctivitis total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Atopic Keratoconjunctivitis market size during the forecast period (2019-2032)?
• At what CAGR, the Atopic Keratoconjunctivitis market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Atopic Keratoconjunctivitis market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Atopic Keratoconjunctivitis market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Atopic Keratoconjunctivitis Epidemiology Insights

• What are the disease risk, burden, and regional/ethnic differences of the Atopic Keratoconjunctivitis?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Atopic Keratoconjunctivitis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Atopic Keratoconjunctivitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Atopic Keratoconjunctivitis?
• Out of all 7MM countries, which country would have the highest prevalent population of Atopic Keratoconjunctivitis during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current options for the Atopic Keratoconjunctivitis treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Atopic Keratoconjunctivitis in the USA, Europe, and Japan?
• What are the Atopic Keratoconjunctivitis marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many Atopic Keratoconjunctivitis companies are developing therapies for the treatment of Atopic Keratoconjunctivitis?
• How many therapies are in-development by each company for Atopic Keratoconjunctivitis treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Atopic Keratoconjunctivitis treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Atopic Keratoconjunctivitis therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the ongoing Atopic Keratoconjunctivitis clinical trials and their status?
• What are the current challenges faced in Atopic Keratoconjunctivitis drug development?
• What are the key designations that have been granted for the emerging therapies for Atopic Keratoconjunctivitis?
• What are the global historical and forecasted Atopic Keratoconjunctivitis market?

Reasons to buy the Atopic Keratoconjunctivitis Market Report

• The Atopic Keratoconjunctivitis Market report will help in developing business strategies by understanding trends shaping and driving the Atopic Keratoconjunctivitis market
• To understand the future market competition in the Atopic Keratoconjunctivitis market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Atopic Keratoconjunctivitis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Atopic Keratoconjunctivitis market
• To understand the future market competition in the Atopic Keratoconjunctivitis market